Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery

Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery

ABSTRACT Adjuvant properties of bacterial cell wall components like MPLA (monophosphoryl lipid A) are well described and have gained FDA approval for use in vaccines such as Cervarix. MPLA is the product of chemically modified lipooligosaccharide (LOS), altered to diminish toxic proinflammatory effe...

Full description

Bibliographic Details
Main Authors:	Kelsey A. Gregg, Erin Harberts, Francesca M. Gardner, Mark R. Pelletier, Corinne Cayatte, Li Yu, Michael P. McCarthy, Jason D. Marshall, Robert K. Ernst
Format:	Article
Language:	English
Published:	American Society for Microbiology 2017-07-01
Series:	mBio
Subjects:	TLR4 adjuvants immunomodulation innate immunity lipid A lipopolysaccharide
Online Access:	https://journals.asm.org/doi/10.1128/mBio.00492-17

Similar Items

Therapeutic Targeting of TLR4 for Inflammation, Infection, and Cancer: A Perspective for Disaccharide Lipid A Mimetics
by: Holger Heine, et al.
Published: (2022-12-01)

Topical application of the anti-microbial chemical triclosan induces immunomodulatory responses through the S100A8/A9-TLR4 pathway
by: Nikki B. Marshall, et al.
Published: (2017-01-01)

Flagellin as a vaccine adjuvant
by: Baofeng Cui, et al.
Published: (2018-04-01)

ProLonged Liposomal Delivery of TLR7/8 Agonist for Enhanced Cancer Vaccine
by: Sehui Kim, et al.
Published: (2023-09-01)

Aminosugar-based immunomodulator lipid A: synthetic approaches
by: Alla Zamyatina
Published: (2018-01-01)

Exploration of Pattern Recognition Receptor Agonists as Candidate Adjuvants
by: Guang Han Ong, et al.
Published: (2021-10-01)

BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant
by: Deepender Kaushik, et al.
Published: (2020-08-01)

Local Innate Responses to TLR Ligands in the Chicken Trachea
by: Neda Barjesteh, et al.
Published: (2016-07-01)

Review: Current trends, challenges, and success stories in adjuvant research
by: Kentner L. Singleton, et al.
Published: (2023-01-01)

Tailored Modulation of Cellular Pro-inflammatory Responses With Disaccharide Lipid A Mimetics
by: Holger Heine, et al.
Published: (2021-03-01)

Stimulation Through CD40 and TLR-4 is an Effective Host Directed Therapy Against Mycobacterium tuberculosis
by: Nargis Khan, et al.
Published: (2016-09-01)

New chimeric TLR7/NOD2 agonist is a potent adjuvant to induce mucosal immune responses
by: Alice Gutjahr, et al.
Published: (2020-08-01)

Silencing SOCS1 via Liposome-Packed siRNA Sustains TLR4-Ligand Adjuvant
by: Dagmar Hildebrand, et al.
Published: (2019-06-01)

Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands
by: Deana N. Toussi, et al.
Published: (2014-04-01)

Co-Delivery of Novel Synthetic TLR4 and TLR7/8 Ligands Adsorbed to Aluminum Salts Promotes Th1-Mediated Immunity against Poorly Immunogenic SARS-CoV-2 RBD
by: Karthik Siram, et al.
Published: (2023-12-01)

Toll-Like Receptor Ligand Based Adjuvant, PorB, Increases Antigen Deposition on Germinal Center Follicular Dendritic Cells While Enhancing the Follicular Dendritic Cells Network
by: Christina Lisk, et al.
Published: (2020-06-01)

TLR2-Deficiency Promotes Prenatal LPS Exposure-Induced Offspring Hyperlipidemia
by: Dayan Cao, et al.
Published: (2019-08-01)

Maintenance of homeostasis by TLR4 ligands
by: Masataka Oda, et al.
Published: (2024-04-01)

TLR5 participates in the TLR4 receptor complex and promotes MyD88-dependent signaling in environmental lung injury
by: Salik Hussain, et al.
Published: (2020-01-01)

An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants
by: Mohammad Enamul Hoque Kayesh, et al.
Published: (2021-11-01)

Precision Vaccinology Approaches for the Development of Adjuvanted Vaccines Targeted to Distinct Vulnerable Populations
by: Branden Lee, et al.
Published: (2023-06-01)

Immunomodulatory Potential of <i>Tinospora cordifolia</i> and CpG ODN (TLR21 Agonist) against the Very Virulent, Infectious Bursal Disease Virus in SPF Chicks
by: Swati Sachan, et al.
Published: (2019-09-01)

A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models
by: Kamel Chettab, et al.
Published: (2023-05-01)

PARTICIPATION OF TLR4 IN ENGULFMENT OF ESCHERICHIA COLI BY HUMAN BLOOD NEUTROPHILS IN PRESENCE OF LIPOPOLYSACCHARIDES
by: S. V. Zubova, et al.
Published: (2014-07-01)

Reactivating Immunity Primed by Acellular Pertussis Vaccines in the Absence of Circulating Antibodies: Enhanced Bacterial Control by TLR9 Rather Than TLR4 Agonist-Including Formulation
by: Floriane Auderset, et al.
Published: (2019-07-01)

Next-Generation Adjuvants: Applying Engineering Methods to Create and Evaluate Novel Immunological Responses
by: Jeremiah Y. Kim, et al.
Published: (2023-06-01)

A novel defined TLR3 agonist as an effective vaccine adjuvant
by: Kwang Hyun Ko, et al.
Published: (2023-01-01)

Evaluation of a Lipopolysaccharide and Resiquimod Combination as an Adjuvant with Inactivated Newcastle Disease Virus Vaccine in Chickens
by: Bal Krishan Sharma, et al.
Published: (2022-06-01)

A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer
by: Hans-Georg Rammensee, et al.
Published: (2019-11-01)

Hyperexpression of TLR2 and TLR4 in patients with ischemic stroke in acute period of the disease
by: L. V. Gankovskaya, et al.
Published: (2020-08-01)

Self‐Assembly of Immune Signals to Program Innate Immunity through Rational Adjuvant Design
by: Michelle L. Bookstaver, et al.
Published: (2023-01-01)

A new model of self-resolving leptospirosis in mice infected with a strain of Leptospira interrogans serovar Autumnalis harboring LPS signaling only through TLR4
by: Bili Xia, et al.
Published: (2017-01-01)

Recent Advances on Small-Molecule Antagonists Targeting TLR7
by: Haoyang Zheng, et al.
Published: (2023-01-01)

Development of a novel TLR8 agonist for cancer immunotherapy
by: Yuxun Wang, et al.
Published: (2020-09-01)

The macrophage infectivity potentiator of Trypanosoma cruzi induces innate IFN-γ and TNF-α production by human neonatal and adult blood cells through TLR2/1 and TLR4
by: Sarra Ait Djebbara, et al.
Published: (2023-05-01)

TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults
by: Rasmus Offersen, et al.
Published: (2012-08-01)

TLR10: An Intriguing Toll-Like Receptor with Many Unanswered Questions
by: Carolina Rego Rodrigues, et al.
Published: (2024-01-01)

Self-Assembled TLR7/8 Agonist-Mannose Conjugate as An Effective Vaccine Adjuvant for SARS-CoV-2 RBD Trimer
by: Changcai Teng, et al.
Published: (2022-12-01)

A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity
by: Fumi Sato-Kaneko, et al.
Published: (2020-06-01)

Spatiotemporally specific roles of TLR4, TNF, and IL-17A in murine endotoxin-induced inflammation inferred from analysis of dynamic networks
by: Ruben Zamora, et al.
Published: (2021-06-01)